FDA’s Temple Sees Sentinel As Important Tool For Confirming And Analyzing Drug Adverse Events

FDA clinical science expert Robert Temple discusses how the Sentinel project – a drug data monitoring initiative – can support the agency’s postmarket drug safety investigations.